RFP, CGN and CGA Opportunities
The Alliance is a community dedicated to connecting healthcare education professionals to promote best practices that improve patient care. To help achieve this, we collect information on research proposals and grants offered through other healthcare-related organizations. If your company is interested in posting a request for grant applications, please contact the Alliance Business Office at firstname.lastname@example.org.
Bristol-Myers Squibb accepts funding requests within the following therapeutic areas of interest. As areas of interest and funding consideration may change periodically, please consult this website frequently. Please note that international funding opportunities may differ.
- Genetically Defined / Rare Diseases
Defense Health Agency (DHA) Research and Development Directorate
The Defense Health Agency (DHA) Research and Development Directorate is offering a new, competitively-funded health services research (HSR) grant opportunity to conduct research with the goal of improving quality and other outcomes in the Military Health System (MHS).
This new effort supports the establishment of DHA as a learning organization committed to generating knowledge about the MHS to achieve better care, better health, and increased military readiness - all at a lower cost. This new funding opportunity is available to both intramural and extramural research organizations. Potential researchers wishing to apply for funding, such as those from universities or military medical research centers and treatment facilities, should check the grants.gov website for the specific announcement. The application deadline is August 23, 2019.
Genentech is seeking to support learning initiatives that demonstrate a strategy that evolves knowledge-based medical education into a “healthcare Improvement” initiative that accelerates the awareness and application of evidence-based medicine, resulting in appropriate care for patients and relevant, measurable, clinical outcomes.
Therapeutic area(s) of interest:
- Non-Malignant Blood Disorders
Indivior supports independent medical education activities that provide for an increased understanding of scientific, clinical, or healthcare issues related to the company’s therapeutic areas of interest.
Therapeutic areas of interest:
- Opioid Use Disorder
To view open RFPs and complete details regarding grant submission, please visit the following site on a regular basis: grants.indivior.com
Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
The Centers for Medicare & Medicaid Services (CMS) recognizes the benefits of measure development by external stakeholders with specific knowledge of clinician and patient perspectives and needs, such as clinical specialty societies, clinical professional organizations, patient advocacy organizations, educational institutions, independent research organizations, health systems, and other entities.
On March 2, 2018, CMS published the “Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program” on Grants.gov. The purpose of this Funding Opportunity is to provide technical and funding assistance in the form of cooperative agreements to entities to develop, improve, update, or expand quality measures for use in the Quality Payment Program (QPP).
For more information and to see the ‘Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program’ search by the title or the Catalog of Federal Domestic Assistance (CFDA) number, 93.986 on Grants.gov.
Novo Nordisk Inc.
Novo Nordisk is committed to supporting independent medical education programs that meet the educational needs of health care professionals (HCPs), patients and the community in ways that measurably grow their knowledge and skills to optimize patient or self care in the following therapeutic areas of interest:
Please visit www.novonordiskgrants.com to apply for educational grants and access the IME Funding Document that provides information about educational priorities and available funding as well as current Request for Proposals (RFPs)/Call for Concept Proposals (CCPs) within these therapeutic areas.
Opiod Anagesic Risk Evaluation and Mitigation Strategy Program Companies (RPC) Continuing Education (CE) Subteam
The 2019 CE Grant Cycle is open to all CE providers interested in receiving funding for REMS-compliant accredited CE programs under RFA 100619. REMS-compliant educational activities must cover all portions of the approved FDA’s Opioid Analgesic REMS Education Blueprint for Healthcare Providers Involved in the Treatment and Monitoring of Patients with Pain “FDA Blueprint”, which can be accessed here.
The RFA can be accessed via the RPC REMS website (click here). The link to the RFA is listed on the right-hand side of the page. The deadline for submission of applications for this RFA is 11:59 pm ET, Friday, 8/23/2019. Beginning Friday, 6/28/2019, applications must be submitted through the RPC grant management system portal, accessible via this link.
Pfizer Independent Grants for Learning & Change (IGLC)
The mission of Pfizer Independent Grants for Learning & Change is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organizations and programs in the United States.
To view open RFPs and complete details, please visit this webpage.
Request for Regional and/or Local Programs regarding Newborn Screening. These educational grants are intended to support qualified organizations in the areas of interest above, but not directly related to our therapies or products.
To respond to this RFP, please complete the Independent Medical Education application https://sgrants.envisionpharma.com/vt_sgrants.
Click here to review the RFP.
When entering proposal into the website, please reference the following:
Therapeutic Area: Genetic Disease
Area of Interest: Pompe Disease and MPS1
RFP Name: 'NBS Peds RFP 19’
Please note that you must answer the question, “Are you responding to an RFP” and select “NBS Peds RFP 19” from the RFP dropdown panel within the grant portal upon submitting your application for this RFP.
Should you have any questions, please contact Lindsey Bigda at email@example.com.
Shionogi accepts funding requests within the following therapeutic areas of interest.
- Gram-negative multidrug-resistant infectious disease (ID)
- Thrombocytopenia associated with chronic liver disease (CLD)
- Opioid-induced Constipation (OIC)
The call for grants (CFG) opportunities will change on a quarterly basis. Please consult our website to identify current opportunities.